What question did this study set out to answer?

To report a case of durable clinical response to the immune checkpoint inhibitor pembrolizumab in a patient with early metastatic recurrence of pure bladder squamous cell carcinoma.

August 20, 2026IJU Case ReportsOpen Access

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

View Full Paper

Ask AI

Bookmark

To report a case of durable clinical response to the immune checkpoint inhibitor pembrolizumab in a patient with early metastatic recurrence of pure bladder squamous cell carcinoma.
Clinical and therapeutic evaluation of a 49-year-old male presenting with pure bladder squamous cell carcinoma in a diverticulum with pelvic nodal involvement.
Administration of neoadjuvant gemcitabine plus cisplatin, robot-assisted radical cystectomy, platinum rechallenge upon recurrence, followed by pembrolizumab therapy and targeted radiotherapy.
Assessment of tumor tissue for predictive biomarkers including programmed cell death ligand-1 (PD-L1) expression, microsatellite status, and tumor mutational burden.
Pembrolizumab achieved a complete response against pulmonary metastases and pleural dissemination despite PD-L1 negativity, microsatellite stability, and low tumor mutational burden.
Isolated hilar lymph node recurrence during therapy was successfully managed with radiotherapy, providing local disease control.
Overall survival reached 41 months from initial diagnosis and 30 months following the emergence of metastatic disease.

Authors

KSKazuma SoyaHimeji Medical Center TFTakeru FujimotoHimeji Medical Center YOYu OsakiKagawa University

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Case report demonstrates a durable complete response to pembrolizumab in metastatic bladder squamous cell carcinoma, highlighting potential immunotherapy efficacy despite negative biomarkers.

Cite This Study

Soya et al. (2026) studied this question.

synapsesocial.com/papers/6a86b56c8a91293e6a1ccc1e https://doi.org/10.1002/iju5.70252

View Full Paper

Ask AI

Bookmark

Implication

Case report demonstrates a durable complete response to pembrolizumab in metastatic bladder squamous cell carcinoma, highlighting potential immunotherapy efficacy despite negative biomarkers.

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

Key Points

Discussion

Implication

Cite This Study

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider